Authors
Latest:
U.S. News & World Report Once Again Ranks Hackensack University Medical Center the 1 Hospital in New JerseyU.S. News & World Report named Hackensack Meridian Hackensack University Medical Center the #1 hospital in New Jersey on its annual Best Hospitals list.
Latest:
Emerging Agents and Future of Small Cell Lung CancerJared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.
Latest:
Dr. Schulte on the PRECISION 1 Trial of Nab-Sirolimus in TSC1/2-Mutated Solid TumorsBrian Schulte, MD, discusses the ongoing phase 2 PRECISION 1 basket trial evaluating the use of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring TSC1/2 mutations.
Latest:
Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral CentersPanelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.
Latest:
Dr. Jacot on Ribociclib Dose Reduction in HR+/HER2– Advanced Breast CancerWilliam Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.
Latest:
Dr Corr on the Rationale for Investigating Rucaparib Maintenance in Endometrial CancerBradley R. Corr, MD, discusses a phase 2 study evaluating rucaparib maintenance therapy in patients with metastatic and recurrent endometrial cancer.
Latest:
Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple MyelomaThe treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.
Latest:
Dr Grunwald on Monitoring Risk Factors for Disease Progression in PVMichael R. Grunwald, MD, discusses the importance of monitoring risk factors associated with disease progression in patients with polycythemia vera.
Latest:
Dr. Shereck Highlights a Day In the Life of an Attending PhysicianEvan B. Shereck, MD, MEd, serves as professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University. In this episode, she highlights the average work day as an attending physician.
Latest:
Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung CancerJohn F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.
Latest:
IU Cancer Researchers Refining Colorectal Cancer Classification, Identifying New Targets for Treatment Using Cutting-Edge, Single-Cell TechnologyAnalyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.
Latest:
Advice for Community Oncologists Treating Patients With R/R MMDrs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.
Latest:
Camidge and Wilfong on Making A Difference Through a Career in Continuing Medical EducationD. Ross Camidge, MD, PhD, and Kadrin Wilfong, MD discuss Wilfong's passion for continuing medical education (CME) and how CME events and resources can make a difference in the care of patients with cancer.
Latest:
Dr. Danila on Examining Immunotherapy in Early-Stage Prostate CancerDaniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.
Latest:
From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI CancerDaniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.
Latest:
HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSBDr Harrington discusses PDS0101 plus pembrolizumab in HPV16+ HNSCC and how the VERSATILE-003 trial may change the HNSCC treatment paradigm.
Latest:
Dr Cardin on the Influence of Comorbidities on Treatment Selection in Pancreatic CancerDana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.
Latest:
Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast CancerRuchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.
Latest:
The Impact of CAR T Cell Therapy on Managing R/R LBCLCAR T cell therapies have shown remarkable clinical success in difficult-to-treat blood cancers. Read one oncologist’s perspective on what current CAR T therapies may offer patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including at earlier points in their disease journey.
Latest:
Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast CancerIsmail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast CancerIrene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.
Latest:
MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALLDoug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).
Latest:
Dr. Vijayvergia on the Efficacy of Pembrolizumab in MSI-H Advanced Gastric CancerNamrata (Neena) Vijayvergia, MD, discusses the efficacy of pembrolizumab with or without chemotherapy in patients with microsatellite instability–high advanced gastric cancer.
Latest:
New Trial Tests Chemotherapy Regimen Following Pancreatic Cancer SurgeryA new clinical trial is testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
Latest:
Patient Experiences Can Affect a Practice’s Financial HealthThe patient experience is a critical factor in the success of any healthcare practice, and its importance is increasing with the rise of health care consumerism.
Latest:
Dr. Bravo-Cordero on the Role of the Extracellular Matrix in Breast Cancer DormancyJose Javier Bravo-Cordero, MD, discusses the role of extracellular matrix proteomics and disseminating tumor cells when regulating the tumor microenvironment to induce dormancy in breast cancer.
Latest:
Closing Remarks on the Treatment of Patients With Metastatic MelanomaExperts share closing remarks and provide advice for clinicians treating patients with metastatic melanoma.
Latest:
Dr Wong on Challenges Incorporating Checkpoint Inhibitors into Curative-Intent Regimens in HNSCCDeborah J. Wong, MD, PhD, discusses challenges incorporating checkpoint inhibitors into curative-intent approaches for patients with head and neck squamous cell carcinoma.
Latest:
Bispecific Targeting CD3 and BCMA Reflect Expanding Options in Multiple MyelomaBispecific antibodies targeting BCMA have shown efficacy in relapsed refractory multiple myeloma, including bispecifics targeting BCMA x CD3.
.jpg?fit=crop&auto=format)
